Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Neoadjuvant for HNSCC
NCT06537011Phase 2Not yet recruiting
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in head and neck squamous cell carcinoma (HNSCC). Primary endpoints: Pathological Complete Response at 1.5 months and Event-Free Survival at 2 years. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06537011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06537011.